It has been shown recently that HDAC6 may induce the expression of PD-L1 in cancer cells via the activation and recruitment of STAT3 transcription factors, as shown in experimental models of pharmacological impairment of HDAC6 or by its genetic abrogation in melanoma [224] and breast cancer [196,237]. The gene discussed is HDAC6; the disease is breast cancer.